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Background 
The influenza virus is a respiratory disease spread by coughing or 
sneezing from an infected person by breathing from one patient to 
another. The global burden of 1 billion infections and between 3 and 5 
million cases of severe illness caused by influenza epidemics is 
projected each year. There are currently two major types of influenza 
vaccine available: the inactivated vaccine (monovalent and protective 
against the strain A (H1N1)) and the live attenuated vaccine. Then a 
different influenza virus was isolated (influenza B) in 1940 and the 
first bivalent vaccine was tested in healthy adults. Many inactive 
vaccines are currently being developed in embryonic chicken eggs 
from propagation. However, a limiting factor is the availability of embryonated chicken eggs, 
and global production is not expected to meet the increasing demand for doses during the 
pandemic season. New influenza A strains with specific HA and NA were reported in the late 
1970s. Since then, in most influenza vaccines, called trivalent influenza vaccine (TIV), two 
influenzas A strains (H1N1 and H3N2 subtypes) and one influenza B strain have been 
included (l.Barberis, 2013). 
 
Reference 
The influenza virus is a member of the family Orthomyxoviridae that consists of an RNA 
genome with a single-stranded negative sense. Based on antigenic variations in viral 
nucleoprotein (NP) and matrix proteins composed of influenza A and B viruses causing 
seasonal epidemics, with an attack rate between 5%-10% to 20%-30% in adults and children 
each year, resulting in 3 to 5 million infections. It is predicted that it will take six months to 
produce seasonal influenza vaccines and move from obtaining the reference strain through 
viral dissemination, purification, inactivation, and eventually to development. An 
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approximate 70-90 percent of people with chronic health conditions accompanying the 
ineffective vaccine is safe in healthy people and 50-70 percent. This causes a higher response 
of mucosal IgA in live attenuated vaccines provided intranasally, and is believed to provide 
immunity from infection from other subtypes. However, since the vaccine contains a live 
virus that is adjusted only to temperatures below 25 8C, recipients are restricted to 
individuals between 5 and 49 years of age (Chen, J.-R, 2011). 
 
Formulation 
World Health Organization (WHO) official recommendation dor quadrivalent vaccine that 
use in 2019-2020 northern hemisphere influenza season. Fluquadri® contained types of  virus 
antigens that are in accordance with the requirements of the Australian Influenza Vaccine 
Committee and WHO recommendations. The quadrivalent inactivated influenza vaccine 
contain 
 A H1N1 pandemic09 (A/Brisbane/02/2018) 
 A H3N2 (A/Kansas/14/2017) 
 B/Colorado/06/2017 (Victoria lineage) 
 B/Phuket/3073/2013 (Yamagata lineage) 
 
The production of the Fluquadri® vaccine used conventional egg inoculation method and 
producing “Split Virus”. The “Split Virus” are purified and suspended in an isotonic solution 
of sodium chloride sodium phosphate. Viral antigens from the four strains included in the 
vaccine are produced separately and then combined to make quadrivalent formulation. 
 
Pharmacodynamic 
The inoculation of antigen prepared from inactivated influenza virus that stimulate specific 
antibody production. Influenza virus vaccine imparts immunity against the influenza virus by 
stimulating production of antibodies that are specific to the disease. Fluquadri® vaccine has 
been shown to induce antibodies to the surface glyprotein, hemagglutinin. The trimeric 
hemagglutinin glycoprotein acts by promoting attachment of the virus to the host cell surface 
resulting in fusion and thereby releasing virions into the cytoplasm. HA protein surface 
consists of two structural element, the head and the stalk where the head is the main target of 
antibodies that provide protection against influenza viruses. The quadrivalent vaccine 
provides active immunization against four types of influenza viruses (two subtypes A and 
two types B). 
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Protection from influenza virus infection has not been correlated with a specific level of 
hemagglutinin inhibition (HI) antibody titer post-vaccination but HI antibody titres have been 
used as a measure of vaccine activity and currently the best available surrogate marker of 
activity that is reasonably likely to predict clinical benefit. Annual influenza vaccination is 
recommended because the types circulating strains of influenza virus may change and mutate 
from year to year and also as immunity declines during the year after vaccination. 
 
Pharmacokinetics 
The inactivated influenza virus vaccine is administered intramuscularly or intradermal 
vaccines. The effectiveness of a vaccine depends on several host factors such as age (usually 
70- 90% effective in healthy people under 65 years of age), underlying health status, genetic 
status and furthermore on antigenic matches between the vaccine and circulating viruses. The 
protective effect of HA vaccine usually occurs within 10 to 14 days of administration. Post- 
vaccine antibody titres in young adults and healthy children generally tend to be high enough 
to provide reistance infection by strains found in vaccines. Some studies have shown that HI 
titers ranging from 1:32 to 1:40 are associated with protection against disease in 
approximately 50% of subjects, and that protection against disease correlates with higher 
titers. This increased response is seen in subjects with the underlying disease (cardiovascular, 
respiratory, and diabetes) who are at increased risk of complications of influenza infection 
and in elderly subjects with low pre- immunization titre. The duration of the immune effect of 
influenza vaccine is generally 6 to 12 months. HA vaccine is not recommended mixed with 
other vaccines in the same syringe or vial. 
 
Vaccine storage 
Vaccines must be stored at temperatures between +2°C - +8°C at all times to maintain their 
potential and effectiveness. the temperature of the vaccine refrigerator should be kept tight at 
temperature +5°C to protect the vaccine from temperature fluctuations that can occur. before 
stocking the vaccine the internal refrigerator temperature must also be stabilized between 
+2°C - +8°C for 7 consecutive days. Refrigerator organization for vaccine are: vaccine 
storage in the refrigerator must be away from the walls of the refrigerator, floor and cold air 
vents, because it can increase the risk of increasing temperatures. Keep it in the middle shelf, 
never store it in the refrigerator door drawer because it can cause the vaccine to be exposed to 
warmer temperatures. Leave space between the vaccine packages, so that good air circulation 
occurs. Keep the vaccine in its original package to protect the vaccine from exposure to light. 
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Keep bottled water in the bottom shelf or refrigerator door to help keep the temperature stable 
in the refrigerator. Temperature monitoring is an important requirement for vaccine 
temperature monitoring. Temperature monitoring devices are calibrated to an accuracy of ± 1 
° C and must be checked for accuracy every year. Temperature monitoring devices also 
become less accurate if the batteries are low, so the battery must be replaced a maximum 
every 6 months. To facilitate the continuous temperature recording of the refrigerator, it can 
use a data logger equipped with a digital screen display so that the temperature can be seen 
visually. This device can save temperature readings that can be downloaded to a computer. 
but, the minimum, maximum and current temperatures still need to be recorded manually as a 
timely alert to any breach in the cold chain (Storage, V. 2009). 
 
Administration 
There are several routes of vaccine administration, in this case, intramuscular injection of 
choice. Intramuscular injection (IM) is giving the vaccine into muscle mass. Injection 
techniques are the most important parameter for ensuring efficient delivery of intramuscular 
vaccines. For  all intramuscular injections, the needle must be long enough to reach muscle 
mass and prevent the vaccine from seeping into the subcutaneous tissue, intramuscular 
injections are administered at a 90-degree angle to the skin, preferably into the anterolateral 
aspect of the thigh or the deltoid muscle of the upper arm, depending on the age of the 
patient. The measuring needle for intramuscular injection is 22-25 gauge. The length of the 
needle and injection site for each  person is based on the size of the muscle, the thickness of 
the adipose tissue at the injection site, the volume of material to be given, the injection 
technique, and the depth at which the drug material will be injected under the surface of the 
muscle. 
 
For most infants (<12 months old), the anterolateral aspect of the thigh is the recommended 
place for injection because it provides a relatively greater muscle mass than a deltoid with a 
1-inch needle is enough to penetrate the thigh muscle. For toddlers (12 Months-2 Years 
Old), anterolateral thigh muscles are preferred with a needle length of at least 1 inch. Deltoid 
muscles are preferred for children aged 3-10 years, with needle lengths ranging from ⅝ to 1 
inch based on technique. Deltoid muscle is preferred for adolescents aged 11-18 years. 
Anterolateral thighs can also be used. For injection into the anterolateral thigh, most 
teenagers will need a 1-1.5 inch needle to ensure intramuscular administration. For adults, 
deltoid muscles are recommended for routine intramuscular vaccination. For men and 
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women weighing <130 lbs (<60 kg), a ⅝ inch needle is sufficient to ensure intramuscular 
injection of deltoid muscle if the injection is performed at an angle of 90 degrees and the 
tissue is not bound. For men and women weighing 130-152 lbs (60-70 kg), a 1-inch needle is 
sufficient. For women weighing 152-200 lbs (70-90 kg) and men weighing 152-260 lbs (70-
118 kg), a needle of 1 to 1.5 inches is recommended. For women weighing> 200 lbs (> 90 
kg) or men weighing> 260 lbs (> 118 kg), a 1.5-inch needle is recommended (Centers for 
Disease Control and Prevention. (2017). 
 
Novel drug delivery system of hemagglutinin vaccine 
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Based on the above table, all influenza vaccines registered in Indonesia in 2019 are all 
inactivated influenza vaccines. Influenza vaccines are developed twice a year to deal with 
changes in the virus. The recommended influenza vaccine for use in Indonesia in 2019 is in 
accordance with the table above. Annual vaccinations for people over six months and high-
risk people, including (pregnant women, parents, people who have health problems or 
diseases) are recommended by the World Health Organization (WHO). 
 
There are several different type of vaccines such as live-attenuated vaccines, inactivated 
vaccines, and (subunit, recombinant, polysaccharide, and conjugate vaccines). All of them 
also have some limitations, for example live-attenuated vaccines because they contain a small 
amount of the weakened live virus, peope with weakened immune systems, long-term health 
problems, or people who’ve had an organ transplant, must be careful and should talk to the 
doctor before receiving the vaccines. Inactivated vaccines is a type of vaccine that is very 
widely used and registered in Indonesia today, its also has some limitations inactivated 
vaccines usually don’t provide immunity (protection) that’s as strong as live vaccines. So its 
may need several doses over time in order to get ongoing immunity against diseases. And 
type vaccines is subunit, recombinant, polysaccharide, and conjugate vaccines, one 
limitation of these vaccines is need booster shots to get ongoing protection against diseases. 
Based on the limitations of the vaccines type we chose to use virosome. 
 
A virosome is a virus-like particle but does not contain or have the genetic makeup of the 
virus. Made like the original virus consisting of a newly formed influenza virus envelope. 
Virosomes are produced from influenza virus through a detergent solubilization and removal 
procedure. Properly reconstituted virosomes retain the cell binding and membrane fusion 
properties of the native virus, mediated by the viral envelope glycoprotein haemagglutinin. 
These functional characteristics of virosomes form the basis for their enhanced 
immunogenicity. First, virosomes represent an antigen presentation system that activates both 
the humoral and the cellular arm of the immune system, such that not only solid antibody 
responses but also cell- mediated immunity is induced. Second, virosomes provide the 
opportunity to incorporate lipophilic or amphiphilic adjuvants in the vaccine for specific 
boosting of the antibody response against the viral haemagglutinin. 
 
Most of the routes for administering vaccines are by injection, which has several 
disadvantages, namely causing injury and causing pain. Therefore, we devised a new method 
for administering vaccines through nasal spray. this has the advantage of not using needles so 
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they do not cause pain, and this route can be local and more targeted which has easy access to 
important parts of the immune system. 
 
This nasal spray method is not recommended for children under 2 years old, pregnant 
women, people who have a history of allergies to influenza vaccines, as well as people aged 
50 years and over. This administartions method is also contraindicated for patients using 
aspirin or salicylic acid (for ages 2-17 years), asthma patients who have a history of wheezing 
in the last 12 months. 
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